Related Experiment Video
Updated: Jun 14, 2026

Three Laboratory Procedures for Assessing Different Manifestations of Impulsivity in Rats
Published on: March 17, 2019
Putamen function and MAOA genotype define genetic and neural subtypes of hyperactivity-impulsivity in ADHD
Yuan Feng1, Yuan Gao1, Qianrong Liu1
1Peking University Sixth Hospital, Peking University Institute of Mental Health, NHC Key Laboratory of Mental Health (Peking University), National Clinical Research Center for Mental Disorders (Peking University Sixth Hospital), Beijing, China.
Background:
Hyperactivity-impulsivity (HI) is a core ADHD symptom associated with the monoamine oxidase A (MAOA) gene. The neurobiological mechanisms underlying HI heterogeneity in children carrying the MAOA risk genotype remain unclear and may involve distinct subtypes.
Methods:
A total of 326 children with ADHD were genotyped for MAOA, including 108 non-risk and 218 risk carriers. Semi-supervised clustering of HI and executive function (EF) scores from the ADHD Rating Scale, Conners' Rating Scale, and BRIEF was used to classify MAOA risk carriers into subtypes, with non-risk patients as the reference. fALFF differences across subtypes, cognitive mediation between brain activity and behavior, and treatment response at follow-up were examined.
Results:
Two subtypes were identified among MAOA risk carriers. Compared with the non-risk group, Subtype 1 showed elevated HI and impaired EF, whereas Subtype 2 showed preserved EF and no HI elevation. Subtype 1 had increased fALFF in the inferior temporal gyrus and higher putamen fALFF than Subtype 2, while Subtype 2 showed increased fALFF in the angular gyrus relative to the non-risk group. Putamen fALFF was associated with inhibition, shifting, emotional control, and the Behavioral Regulation Index (BRI), and mediation analysis suggested an indirect effect on HI via the BRI. After 4 weeks of medication, Subtype 2 showed greater improvement in conduct problems and anxiety.
Conclusion:
Putamen function may underlie HI heterogeneity among MAOA risk carriers and was associated with better EF, milder symptoms, and greater treatment response.
More Related Videos
13:09Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol
Published on: April 1, 2018
10:02Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
Published on: March 12, 2020
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Drugs Affecting Neurotransmitter Synthesis
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drugs Affecting Neurotransmitter Release or Uptake
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...